HBM HOLDINGS-B(02142) has entered into an exclusive licensing agreement and equity partnership agreement with Solstice Oncology for HBM4003.

HBM HOLDINGS-B (02142) announced that the company has entered into an exclusive licensing agreement and equity partnership agreement with Solstice Oncology, a clinical-stage biotechnology company founded by multiple large venture capital firms. Under the agreements, the company agrees to grant Solstice Oncology exclusive rights to develop and commercialize its clinical-stage combination asset HBM4003 outside of Greater China. According to the terms of the agreements, the company is eligible to receive an upfront payment of over $105 million, including a $50 million initial payment, a $5 million near-term payment, and over $50 million worth of equity issued to the company by Solstice Oncology. In addition, the company is also eligible to receive up to an additional $1.1 billion in development, regulatory, and commercial milestone payments, as well as tiered royalties based on net sales of HBM4003 outside of Greater China, depending on the achievement of certain future events. The company will leverage this opportunity to strengthen its global collaboration network through innovative partnership models, maximizing the scientific and commercial value of the company's technology platform. By entering into these agreements, the company aims to accelerate the global development and commercialization of HBM4003 outside of Greater China through collaboration with experienced investment firms to establish a global biotechnology company focused on the development of HBM4003. This collaborative model not only enables long-term value creation but also allows the company to actively participate in and drive the global development process of this asset.